Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.22 CAD | +4.76% | +15.79% | +4.76% |
04-08 | Helix BioPharma Corp. announced that it has received CAD 1.915 million in funding | CI |
03-28 | Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in funding | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 42M 57.42M 3.35B |
---|---|---|---|---|---|
Net income 2022 | -6M -8.2M -478M | Net income 2023 | -6M -8.2M -478M | EV / Sales 2022 | - |
Net cash position 2022 | 784K 1.07M 62.45M | Net cash position 2023 | 808K 1.1M 64.36M | EV / Sales 2023 | - |
P/E ratio 2022 |
-4.33
x | P/E ratio 2023 |
-6.45
x | Employees | 9 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 84.24% |
1 day | +4.76% | ||
1 week | +15.79% | ||
Current month | +22.22% | ||
1 month | +22.22% | ||
3 months | +10.00% | ||
6 months | +10.00% | ||
Current year | +4.76% |
Managers | Title | Age | Since |
---|---|---|---|
Jacek Antas
CEO | Chief Executive Officer | - | 17/04/22 |
Director of Finance/CFO | 59 | 02-13 | |
Chief Tech/Sci/R&D Officer | - | 31/08/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 17/04/22 | |
Jacek Antas
CEO | Chief Executive Officer | - | 17/04/22 |
Malgorzata Laube
BRD | Director/Board Member | - | 07/12/22 |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 0.22 | +4.76% | 3,505 |
26/04/24 | 0.21 | 0.00% | 15,300 |
25/04/24 | 0.21 | +7.69% | 18,100 |
24/04/24 | 0.195 | +2.63% | 2,000 |
23/04/24 | 0.19 | 0.00% | 20,272 |
Delayed Quote Toronto S.E., April 29, 2024 at 08:20 pm
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.76% | 35.2M | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- HBP Stock